Older women with breast cancer are underrepresented in clinical trials, and data on the effects of adjuvant chemotherapy in such patients are scant. We tested for the noninferiority of capecitabine as compared with standard chemotherapy in women with breast cancer who were 65 years of age or older
SummaryCapecitabine, a 5-fluorouracil prodrug, is increasingly used in breast cancer due to its more...
Purpose: Information on the tolerability and efficacy of adjuvant chemoendocrine therapy for older w...
Most patients with breast cancer age ≥ 65 years (ie, older patients) are eligible for adjuvant hormo...
Older women with breast cancer are underrepresented in clinical trials, and data on the effects of a...
Older women with breast cancer are underrepresented in clinical trials, and data on the effects of a...
PURPOSE Older women with breast cancer remain under-represented in clinical trials. The Cancer and L...
Background. Randomized clinical trials have shown the efficacy of adjuvant chemotherapy in treating ...
PURPOSE Few data are available regarding the influence of adjuvant capecitabine on long-term surviva...
PURPOSE Few data are available regarding the influence of adjuvant capecitabine on long-term surviva...
Background: Adjuvant chemotherapy of elderly women is currently perceived as one of the priorities i...
Adjuvant chemotherapy of elderly women is currently perceived as one of the priorities in breast can...
Aims Adjuvant chemotherapy is recommended as a treatment for women with high recurrence risk early ...
PURPOSE: Few data are available regarding the influence of adjuvant capecitabine on long-term surviv...
Aims Adjuvant chemotherapy is recommended as a treatment for women with high recurrence risk early ...
PURPOSE: Few data are available regarding the influence of adjuvant capecitabine on long-term surviv...
SummaryCapecitabine, a 5-fluorouracil prodrug, is increasingly used in breast cancer due to its more...
Purpose: Information on the tolerability and efficacy of adjuvant chemoendocrine therapy for older w...
Most patients with breast cancer age ≥ 65 years (ie, older patients) are eligible for adjuvant hormo...
Older women with breast cancer are underrepresented in clinical trials, and data on the effects of a...
Older women with breast cancer are underrepresented in clinical trials, and data on the effects of a...
PURPOSE Older women with breast cancer remain under-represented in clinical trials. The Cancer and L...
Background. Randomized clinical trials have shown the efficacy of adjuvant chemotherapy in treating ...
PURPOSE Few data are available regarding the influence of adjuvant capecitabine on long-term surviva...
PURPOSE Few data are available regarding the influence of adjuvant capecitabine on long-term surviva...
Background: Adjuvant chemotherapy of elderly women is currently perceived as one of the priorities i...
Adjuvant chemotherapy of elderly women is currently perceived as one of the priorities in breast can...
Aims Adjuvant chemotherapy is recommended as a treatment for women with high recurrence risk early ...
PURPOSE: Few data are available regarding the influence of adjuvant capecitabine on long-term surviv...
Aims Adjuvant chemotherapy is recommended as a treatment for women with high recurrence risk early ...
PURPOSE: Few data are available regarding the influence of adjuvant capecitabine on long-term surviv...
SummaryCapecitabine, a 5-fluorouracil prodrug, is increasingly used in breast cancer due to its more...
Purpose: Information on the tolerability and efficacy of adjuvant chemoendocrine therapy for older w...
Most patients with breast cancer age ≥ 65 years (ie, older patients) are eligible for adjuvant hormo...